GSK 6-K
GSK plc (GSK)
6-K
2026-09-09
For: 2026-09-09
View Original
Added on
September 09, 2026
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR
15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the
month of September 2026
Commission
File Number 001-15170
GSK plc
(Translation
of registrant's name into English)
79 New Oxford Street, London, WC1A 1DG
(Address
of principal executive office)
Indicate
by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.
Form
20-F . . . .X. . . . Form 40-F . . . . . . . .
GSK plc (the
'Company')
2026 Performance Share Plan Award - Roanne Parry
2026 Performance Share Plan Award
On 8 September 2026, the Company granted a conditional
share award to Roanne Parry, a Person Discharging Managerial
Responsibilities ('PDMR'), under the GlaxoSmithKline 2017
Performance Share Plan ('the Plan').
The Plan allows a performance-related opportunity in the form of
conditional awards to be granted to senior executives in the Group,
including the Executive Directors and other PDMRs. Ms Parry became
eligible for the award following her joining GSK as Chief People
Officer and an Executive Committee member on 1 May
2026.
Under the terms of the Plan, conditional awards are granted over a
specific number of Ordinary Shares or American Depositary Shares
('ADS'), and the percentage of the award that ultimately vests is
dependent on the level of achievement against performance measures
set by the Remuneration Committee. The performance measures for Ms
Parry's award are the same as those applicable to the 2026 awards
granted to other Executive Committee members, as detailed within
the announcement of 16 February
2026.
The performance period for the awards is the three financial years
from 1 January 2026 to 31 December 2028.
Notes
1.
To the extent that each element of a conditional award does not
vest at the end of the three-year performance period, it will
lapse.
2.
Ms Parry was granted a conditional award of Ordinary Shares under
the terms of the GlaxoSmithKline 2017 Performance Share
Plan.
3.
Dividends will accrue on the conditional award of Ordinary Shares
during the performance period but will only vest to the extent that
the award vests at the end of the performance period. These
dividends are not included in the figures below.
Transaction notification
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||
|
a)
|
Name
|
Roanne Parry
|
|
|
b)
|
Position/status
|
Chief People Officer
|
|
|
c)
|
Initial
notification/amendment
|
Initial notification
|
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||
|
a)
|
Name
|
GSK plc
|
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||
|
a)
|
Description
of the financial instrument
|
Ordinary shares of 31 ¼ pence each ('Ordinary
Shares')
ISIN: GB00BN7SWP63
|
|
|
b)
|
Nature
of the transaction
|
A conditional award of Ordinary Shares under the Company's 2017
Performance Share Plan
|
|
|
c)
|
Price(s)
and volume(s)
|
Price(s)
|
Volume(s)
|
|
£18.3750
|
85,714
|
||
|
d)
|
Aggregated
information
|
N/A (single transaction)
|
|
|
Aggregated
volume
Price
|
|
||
|
e)
|
Date
of the transaction
|
2026-09-08
|
|
|
f)
|
Place
of the transaction
|
N/A
|
|
About GSK
GSK is a global biopharma company with a purpose to unite science,
technology, and talent to get ahead of disease together. Find out
more at www.gsk.com.
Registered in England & Wales:
No.
3888792
Registered Office:
79
New Oxford Street
London
WC1A
1DG
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorised.
|
|
GSK plc
|
|
|
(Registrant)
|
|
|
|
|
Date: September
09, 2026
|
|
|
|
|
|
|
By:/s/ VICTORIA
WHYTE
--------------------------
|
|
|
|
|
|
Victoria Whyte
|
|
|
Authorised
Signatory for and on
|
|
|
behalf
of GSK plc
|